PharmacoEconomics

Pharmacoeconomics · ISSN (e) 1179-2027 · 4 papers in corpus
other 2026
NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties
doi:10.1007/s40273-026-01596-2 ·PMID:41722022
other 2023
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?
doi:10.1007/s40273-022-01230-x ·PMID:36656509

BACKGROUND: Current practice in health technology assessment (HTA) of pharmaceuticals conducts cost-effectiveness analyses (CEAs) based on a static price or the estimated price at market launch. Recent publications suggest incorporating dyn…

review 2022
Economic Implications of Endometriosis: A Review
doi:10.1007/s40273-022-01211-0 ·PMID:36344867

Endometriosis is a chronic inflammatory disease that can have serious physical and emotional consequences for patients in terms of pain, quality of life, and infertility. Despite affecting about 10% of women, the pathophysiology and economi…

other 2006
Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population
doi:10.2165/00019053-200624010-00005 ·PMID:16445303

INTRODUCTION: Recent literature indicates that interstitial cystitis (IC) may affect 20% of women and a smaller proportion of men, although many individuals with IC may be misdiagnosed or remain undiagnosed. Factors that can contribute to t…